Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT05172258
Title Testing the Addition of an Anti-cancer Drug, Ipatasertib, to the Usual Immunotherapy Treatment (Pembrolizumab) in Patients With Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors National Cancer Institute (NCI)

head and neck squamous cell carcinoma

hypopharynx cancer

oral cavity cancer

laryngeal squamous cell carcinoma

oropharynx cancer


Ipatasertib + Pembrolizumab


Age Groups: senior | adult
Covered Countries USA

No variant requirements are available.